EU PV for Retapamulin-Prescribing

GlaxoSmithKline1 enrolled

Overview

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Impetigo

Interventions

RetapamulinDRUG

Prescription for retapamulin

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * The study population will consist of all registered "research standard" patients on GPRD, as evaluated annually for five years. For each year of observation, the denominator of persons will be patients registered for at least one month during the prior calendar year. Hence, the five-year reporting period for distinct, non-overlapping, non-cumulative prescription use and will categorize persons by date of birth (mm/dd/year). Exclusion Criteria: * Enrollment in GPRD of less than one month duration.

Outcomes

Primary Outcomes

Prescription for retapamulin

Time frame: First prescription in database for each calendar year between January 2007 and December 2011

Secondary Outcomes

Co-prescription of retapamulin and topical mupirocin

Time frame: First same-day prescriptions for both medicines in database for each calendar year between January 2007 and December 2011

Co-prescription of retapamulin and topical fusidic acid

Time frame: First same-day prescriptons for both medicines in database for each calendar year between January 2007 and December 2011